Daniel P. McKee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Daniel P. McKee has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
C. Peine
Hennepin County Medical Center, Minneapolis, MN, USA
1 shared publication- Erik A. Ovrom
Mayo Clinic Alix School of Medicine, Rochester, MN 55905, USA
1 shared publication J. Daniel
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA
1 shared publicationJ. F. Knox
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA
1 shared publicationJ. Franco
Division of Gastroenterology and Hepatology, Medical College of Wisconsin, Milwaukee, WI, USA
1 shared publication- Jasmohan Singh Bajaj
Richmond VA Medical Center, Richmond, Virginia, USA
1 shared publication
Latest Publications
- Open Access
- 7 April 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 1119
A Comprehensive Review of the Genetic and Epigenetic Contributions to the Development of Fibromyalgia
This narrative review summarizes the current knowledge of the genetic and epigenetic contributions to the development of fibromyalgia (FM). Although there is no single gene that results in the development of FM, this study reveals that certain polymorphisms in genes involved in the catecholaminergic pathway, the serotonergic pathway, pain processing, oxidative stress, and inflammation may influence susceptibility to FM and the severity of its symptoms. Furthermore, epigenetic changes at the DNA level may lead to the development of FM. Likewise, microRNAs may impact the expression of certain proteins that lead to the worsening of FM-associated symptoms.
- 7 April 2023
- Published by MDPI AG in Biomedicines
- Vol. 11 (4) , 1119
Open AccessA Comprehensive Review of the Genetic and Epigenetic Contributions to the Development of Fibromyalgia
This narrative review summarizes the current knowledge of the genetic and epigenetic contributions to the development of fibromyalgia (FM). Although there is no single gene that results in the development of FM, this study reveals that certain polymorphisms in genes involved in the catecholaminergic pathway, the serotonergic pathway, pain processing, oxidative stress, and inflammation may influence susceptibility to FM and the severity of its symptoms. Furthermore, epigenetic changes at the DNA level may lead to the development of FM. Likewise, microRNAs may impact the expression of certain proteins that lead to the worsening of FM-associated symptoms.
- Open Access
- 3 November 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (10) , 1189-1193
High‐dose vitamin E supplementation does not diminish ribavirin‐associated haemolysis in hepatitis C treatment with combination standard α‐interferon and ribavirin
Summary: Background: Ribavirin is associated with haemolytic anaemia. Antioxidants have been reported to decrease severity of this anaemia.Aim: To determine effect of vitamin E supplementation on ribavirin‐associated haemolysis in chronic hepatitis C treated with standardα‐interferon and ribavirin.Methods: Fifty‐one naive chronic hepatitis C patients were randomized to receive eitherα‐interferon/ribavirin therapy (control) or therapy plus vitamin E 800 IU b.d. with 24‐week follow‐up. Alanine aminotransferase ALT, haemoglobin and reticulocyte percentage were monitored. Symptoms and health‐related quality of life were also monitored at each visit.Results: Forty‐seven subjects were treated (27 vitamin E /20 controls). Thirteen withdrew because of adverse effects or non‐compliance. Groups were similar in demographics, genotype and baseline lab indices. Comparison with baseline, treatment and follow‐up values showed a significant haemoglobin and ALT reduction in both groups. There was no significant difference in haemoglobin and reticulocyte percentage between groups. Sustained viral response was not significantly different between vitamin E (11/18) and control (6/16) groups. Three patients required ribavirin dose‐reduction in the vitamin E group compared with two controls. Health‐related quality of life during and end‐of‐treatment was not different between groups.Conclusions: Vitamin E supplementation alone during standardα‐interferon and ribavirin therapy does not appear to diminish ribavirin‐associated haemolysis.
- 3 November 2004
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 20 (10) , 1189-1193
Open AccessHigh‐dose vitamin E supplementation does not diminish ribavirin‐associated haemolysis in hepatitis C treatment with combination standard α‐interferon and ribavirin
Summary: Background: Ribavirin is associated with haemolytic anaemia. Antioxidants have been reported to decrease severity of this anaemia.Aim: To determine effect of vitamin E supplementation on ribavirin‐associated haemolysis in chronic hepatitis C treated with standardα‐interferon and ribavirin.Methods: Fifty‐one naive chronic hepatitis C patients were randomized to receive eitherα‐interferon/ribavirin therapy (control) or therapy plus vitamin E 800 IU b.d. with 24‐week follow‐up. Alanine aminotransferase ALT, haemoglobin and reticulocyte percentage were monitored. Symptoms and health‐related quality of life were also monitored at each visit.Results: Forty‐seven subjects were treated (27 vitamin E /20 controls). Thirteen withdrew because of adverse effects or non‐compliance. Groups were similar in demographics, genotype and baseline lab indices. Comparison with baseline, treatment and follow‐up values showed a significant haemoglobin and ALT reduction in both groups. There was no significant difference in haemoglobin and reticulocyte percentage between groups. Sustained viral response was not significantly different between vitamin E (11/18) and control (6/16) groups. Three patients required ribavirin dose‐reduction in the vitamin E group compared with two controls. Health‐related quality of life during and end‐of‐treatment was not different between groups.Conclusions: Vitamin E supplementation alone during standardα‐interferon and ribavirin therapy does not appear to diminish ribavirin‐associated haemolysis.